Tech Company Financing Transactions
Amorcyte Funding Round
Amorcyte, based in Allendale, secured investment capital from Novitas Capital.
Transaction Overview
Company Name
Announced On
10/23/2006
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Novitas Capital (Paul Schmitt)
Proceeds Purpose
Amorcyte expects patient accrual for its 40-patient Phase I clinical trial to be completed in December. The Phase I trial is now open at the Emory University School of Medicine in Atlanta, Georgia under Principal Investigator, Arshed A. Quyyumi, MD, FRCP, FACC. Amorcyte is in final negotiations to open the trial at two other leading cardiology centers. Amorcyte is actively recruiting patients for the trial.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4 Pearl Ct. C
Allendale, NJ 07401
USA
Allendale, NJ 07401
USA
Phone
Website
Email Address
Overview
The company is developing cell therapy products to treat cardiovascular disease, has secured additional funding to complete its first Phase I trial and pursue additional cell therapy opportunities for cardiac and vascular diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/23/2006: Enfora venture capital transaction
Next: 10/24/2006: Innovative Biosensors venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs